Myelofibrosis (MF) is the most severe form of Philadelphia–negative myeloproliferative neoplasms (MPNs), characterized by high risk of leukemic transformation and reduced survival. Neoplastic transformation is linked to somatic mutations in JAK/STAT pathway arising in the hematopoietic stem cell compartment, while MF pathology is defined by clonal myeloproliferation, extramedullary hematopoiesis with splenomegaly, chronic inflammation and extensive bone marrow fibrosis. Currently, the molecular basis of abnormal cytokine production and the altered interaction between malignant hematopoietic cells and the bone marrow microenvironment in MF pathogenesis remains unclear, and JAK1/2 inhibitors, while effective in reducing splenomegaly and inflammation-related symptoms, fail to address BM fibrosis and disease burden in most patients. A key mediator in bone marrow fibrosis development is Osteopontin (OPN), a pro-fibrotic molecule induced by MAPK signalling and JAK/STAT pathway hyperactivation driving MF pathogenesis. This study aimed at identifying a rapidly translatable and effective therapeutic strategy to counteract OPN production and provide a new potential druggable approach to restore bone marrow microenvironment in MF patients.
P007 | Pre-clinical efficacy of a novel combined pharmacological approach targeting JAK and ERK in a myelofibrosis mouse model / Bertesi, M.. - In: HAEMATOLOGICA. - ISSN 1592-8721. - ELETTRONICO. - 111:(2026), pp. 0-0. [10.3324/haematol.2026.s1.80]
P007 | Pre-clinical efficacy of a novel combined pharmacological approach targeting JAK and ERK in a myelofibrosis mouse model
A. M. Vannucchi
2026
Abstract
Myelofibrosis (MF) is the most severe form of Philadelphia–negative myeloproliferative neoplasms (MPNs), characterized by high risk of leukemic transformation and reduced survival. Neoplastic transformation is linked to somatic mutations in JAK/STAT pathway arising in the hematopoietic stem cell compartment, while MF pathology is defined by clonal myeloproliferation, extramedullary hematopoiesis with splenomegaly, chronic inflammation and extensive bone marrow fibrosis. Currently, the molecular basis of abnormal cytokine production and the altered interaction between malignant hematopoietic cells and the bone marrow microenvironment in MF pathogenesis remains unclear, and JAK1/2 inhibitors, while effective in reducing splenomegaly and inflammation-related symptoms, fail to address BM fibrosis and disease burden in most patients. A key mediator in bone marrow fibrosis development is Osteopontin (OPN), a pro-fibrotic molecule induced by MAPK signalling and JAK/STAT pathway hyperactivation driving MF pathogenesis. This study aimed at identifying a rapidly translatable and effective therapeutic strategy to counteract OPN production and provide a new potential druggable approach to restore bone marrow microenvironment in MF patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
13275-Article Text-90503-1-10-20260304.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
302.17 kB
Formato
Adobe PDF
|
302.17 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



